dbo:abstract
|
- Vaccinia immune globulin (VIG) is made from the pooled blood of individuals who have been inoculated with the smallpox vaccine. The antibodies these individuals developed in response to the smallpox vaccine are removed and purified. This results in VIG. It can be administered intravenously. It is used to treat individuals who have developed progressive vaccinia after smallpox vaccination. It was also used along with cidofovir for the 2003 Midwest monkeypox outbreak as concomitant therapy to reduce the serious side effects of smallpox vaccine. In addition, CDC states that use of VIGIV may be considered for postexposure prophylaxis of monkeypox in exposed individuals who cannot receive postexposure vaccination with smallpox vaccine because of severe T-cell function immunodeficiency. (en)
|
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 15859 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- Vaccinia immune globulin (VIG) is made from the pooled blood of individuals who have been inoculated with the smallpox vaccine. The antibodies these individuals developed in response to the smallpox vaccine are removed and purified. This results in VIG. It can be administered intravenously. It is used to treat individuals who have developed progressive vaccinia after smallpox vaccination. (en)
|
rdfs:label
|
- Vaccinia immune globulin (en)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |